Climb Bio (CLYM) Retained Earnings (2020 - 2026)
Climb Bio (CLYM) reported Retained Earnings of -$303.4 million for Q1 2026, down 106183.92% on a YoY basis from N/an in Q1 2025, and down 4.72% quarter-over-quarter from -$289.7 million in Q4 2025.
Climb Bio (CLYM) Retained Earnings (2020 - 2026) Analysis & Trends
Climb Bio has reported Retained Earnings for 7 years, with the latest figure at -$303.4 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 106183.92% year-over-year to -$303.4 million; the trailing twelve-month figure through Mar 2026 stood at -$303.4 million (down 106183.92% YoY), and the FY2025 full-year result was -$289.7 million, down 1259782.61% from the prior year.
- Retained Earnings for Q1 2026 stood at -$303.4 million, down from -$289.7 million in the prior quarter.
- The five-year high for Retained Earnings was $286000.0 in Q1 2025, with the low at -$303.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$111.5 million across 5 years, with a median of -$52.0 million in 2022.
- The largest YoY upside for Retained Earnings was 1250.0% in 2024 against a maximum downside of 2013172.73% in 2024.
- Climb Bio's Retained Earnings stood at -$120.9 million in 2022, then surged by 100.0% to -$2000.0 in 2023, then jumped by 1250.0% to $23000.0 in 2024, then slumped by 1259782.61% to -$289.7 million in 2025, then declined by 4.72% to -$303.4 million in 2026.
- The last three Retained Earnings figures came in at -$303.4 million (Q1 2026), -$289.7 million (Q4 2025), and -$272.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | -303.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -303.40 Mn |
| Dec 31, 2025 | -289.73 Mn |
| Sep 30, 2025 | -272.21 Mn |
| Jun 30, 2025 | -259.32 Mn |
| Mar 31, 2025 | 286,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | -221.46 Mn |
| Jun 30, 2024 | -212.57 Mn |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | -11,000.00 |
| Jun 30, 2023 | -35,000.00 |
| Mar 31, 2023 | -95,000.00 |
| Dec 31, 2022 | -120.86 Mn |
| Sep 30, 2022 | -581,000.00 |
| Jun 30, 2022 | -103.40 Mn |
| Mar 31, 2022 | -521,000.00 |
| Dec 31, 2021 | -123,000.00 |
| Sep 30, 2021 | -65.10 Mn |
| Jun 30, 2021 | -55.50 Mn |
| Dec 31, 2020 | -28.14 Mn |